Aliases & Classifications for Prostatitis

MalaCards integrated aliases for Prostatitis:

Name: Prostatitis 12 72 51 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:14654
ICD10 32 N41 N41.9
ICD9CM 34 601 601.9
MeSH 41 D011472
NCIt 46 C26866
UMLS 69 C0033581

Summaries for Prostatitis

MalaCards based summary : Prostatitis is related to prostate sarcoma and prostatic hyperplasia, benign, and has symptoms including prostatism An important gene associated with Prostatitis is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Acetaminophen and Cycloserine have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 72 Prostatitis is inflammation of the prostate gland. Prostatitis is classified into acute, chronic,... more...

Related Diseases for Prostatitis

Diseases related to Prostatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 971)
# Related Disease Score Top Affiliating Genes
1 prostate sarcoma 34.1 KLK3 NKX3-1
2 prostatic hyperplasia, benign 33.7 ADRA1A KLK3 PDE5A
3 prostate cancer 33.6 KLK3 MSMB NKX3-1 PROS1 TGFB1 VDR
4 kaposi sarcoma 31.0 CXCL8 IL6 TNF
5 cystitis 29.9 CXCL8 IL6 TNF
6 breast disease 29.9 KLK3 TGFB1 TNF
7 alpha-2-macroglobulin deficiency 29.7 KLK3 PROS1
8 choroiditis 29.7 IL10 TNF
9 spinal cord injury 29.7 CXCL8 IL6 TNF
10 pulmonary tuberculosis 29.7 IL10 TNF VDR
11 posterior urethral valves 29.5 IL6 TGFB1 TNF
12 microscopic polyangiitis 29.4 IL10 TNF
13 paracoccidioidomycosis 29.3 IL10 IL6 TNF
14 melioidosis 29.3 IL10 IL6 TNF
15 mycobacterium tuberculosis 1 29.3 IL10 TNF VDR
16 osteoarthritis 29.3 CXCL8 IL1B IL6 TGFB1 TNF
17 fasciitis 29.2 CXCL8 IL6 TNF
18 immune suppression 29.2 IL10 IL6
19 acute pyelonephritis 29.0 CXCL8 IL10 IL6
20 pouchitis 29.0 CXCL8 IL10
21 obstructive jaundice 28.9 CXCL8 IL6 TNF
22 esophagitis 28.9 CXCL8 IL1B IL6 TGFB1
23 echinococcosis 28.9 IL10 IL6 TNF
24 reactive arthritis 28.8 IL10 IL6 TNF
25 filariasis 28.8 IL10 IL6 TNF
26 laryngitis 28.8 IL1B IL6 TGFB1 TNF
27 vaginitis 28.8 CXCL8 IL1B IL6
28 arteries, anomalies of 28.8 IL1B IL6 TNF
29 osteoporosis 28.8 IL1B IL6 TGFB1 TNF VDR
30 endometriosis 28.6 CXCL8 IL1B IL6
31 anterior uveitis 28.6 IL6 TNF
32 endocarditis 28.6 CXCL8 IL10 IL6 TNF
33 haemophilus influenzae 28.5 CXCL8 IL1B TNF
34 periodontal disease 28.4 CXCL8 IL1B IL6 TNF
35 fatty liver disease 28.4 IL1B IL6 TNF
36 brucellosis 28.3 CXCL8 IL10 IL6 TNF
37 q fever 28.3 IL10 IL1B TNF
38 alcoholic hepatitis 28.3 CXCL8 IL10 IL6 TNF
39 synovitis 28.3 CXCL8 IL1B IL6 TNF
40 wegener granulomatosis 28.3 CXCL8 IL10 IL6 TNF
41 chlamydia 28.2 CXCL8 IL10 IL1B IL6 TNF
42 gingivitis 28.1 CXCL8 IL1B IL6 TNF
43 monocytic leukemia 28.1 CXCL8 IL1B IL6 TNF
44 pulmonary fibrosis, idiopathic 28.1 CXCL8 IL1B TGFB1 TNF
45 leishmaniasis 28.0 IL10 IL1B TGFB1 TNF
46 myocardial infarction 28.0 IL10 IL1B IL6 PDE5A TNF
47 pyelonephritis 28.0 CXCL8 IL10 IL1B IL6 TNF
48 helicobacter pylori infection 28.0 CXCL8 IL10 IL1B TNF
49 acquired immunodeficiency syndrome 28.0 IL10 IL1B IL6 TNF
50 periodontitis 27.9 CXCL8 IL10 IL1B IL6 TNF

Comorbidity relations with Prostatitis via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Chronic Myocardial Ischemia Epididymo-Orchitis
Ischemic Heart Disease Prostate Calculus
Prostate Cancer Prostatic Hypertrophy
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatitis:



Diseases related to Prostatitis

Symptoms & Phenotypes for Prostatitis

UMLS symptoms related to Prostatitis:


prostatism

GenomeRNAi Phenotypes related to Prostatitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 IL1B TGFB1 TNF ADRA1A CXCL8 IL10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 IL1B TGFB1 TNF ADRA1A CXCL8 IL10

MGI Mouse Phenotypes related to Prostatitis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 TNF IL6 VDR ADRA1A PROS1 IL10
2 endocrine/exocrine gland MP:0005379 9.91 TNF IL6 MSMB VDR NKX3-1 IL10
3 digestive/alimentary MP:0005381 9.88 TNF IL6 VDR NKX3-1 IL10 TGFB1
4 integument MP:0010771 9.87 TNF IL6 VDR PROS1 IL10 TGFB1
5 muscle MP:0005369 9.8 TNF IL6 VDR ADRA1A PROS1 IL10
6 neoplasm MP:0002006 9.7 TNF IL6 MSMB NKX3-1 IL10 TGFB1
7 reproductive system MP:0005389 9.5 TNF IL6 MSMB VDR NKX3-1 IL10
8 skeleton MP:0005390 9.17 IL1B TNF IL6 VDR NKX3-1 IL10

Drugs & Therapeutics for Prostatitis

Drugs for Prostatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Cycloserine Approved Phase 4,Phase 3 68-41-7 6234 401
3
Acetylcholine Approved Phase 4,Phase 3,Phase 2 51-84-3 187
4
Methyltestosterone Approved Phase 4 58-18-4 6010
5
Testosterone Approved, Investigational Phase 4 58-22-0 6013
6
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
7
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
8
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
9
Cefoxitin Approved Phase 4 35607-66-0 441199
10
Cilastatin Approved, Investigational Phase 4 82009-34-5 6435415 5280454
11
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
12
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
13 Prulifloxacin Investigational Phase 4,Phase 2 123447-62-1
14 Cholinergic Agents Phase 4,Phase 3,Phase 2
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Early Phase 1
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
17 Analgesics Phase 4,Phase 3,Phase 2
18 Anti-Anxiety Agents Phase 4,Phase 3
19 Anticonvulsants Phase 4,Phase 3
20 calcium channel blockers Phase 4,Phase 3
21 Calcium, Dietary Phase 4,Phase 3,Phase 2
22 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
23 Psychotropic Drugs Phase 4,Phase 3
24 Tranquilizing Agents Phase 4,Phase 3
25 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
26 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
27 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antitubercular Agents Phase 4,Phase 3
29 Fluoroquinolones Phase 4,Phase 3,Phase 2
30 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
31 Permixon Phase 4,Phase 3
32 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2
33 Antimetabolites Phase 4,Phase 3
34 Renal Agents Phase 4,Phase 3,Phase 2
35 abobotulinumtoxinA Phase 4,Phase 3,Phase 2
36 Botulinum Toxins Phase 4,Phase 3,Phase 2
37 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 2
38 Neuromuscular Agents Phase 4,Phase 3,Phase 2
39 onabotulinumtoxinA Phase 4,Phase 3,Phase 2
40 Anabolic Agents Phase 4
41 Androgens Phase 4,Early Phase 1
42 Antineoplastic Agents, Hormonal Phase 4
43 Hormone Antagonists Phase 4,Phase 3,Early Phase 1
44 Hormones Phase 4,Phase 3,Early Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Early Phase 1
46 Pharmaceutical Solutions Phase 4,Phase 3
47 Testosterone 17 beta-cypionate Phase 4
48
Testosterone enanthate Phase 4 315-37-7 9416
49 Testosterone undecanoate Phase 4
50 Phosphodiesterase 5 Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 66)

# Name Status NCT ID Phase Drugs
1 Treatment of Chronic Bacterial Prostatitis Completed NCT02130713 Phase 4 Third generation fluoroquinolone
2 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
3 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Completed NCT02246361 Phase 4
4 Botox as a Treatment for Interstitial Cystitis in Women Completed NCT00194610 Phase 4 Botox
5 TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
6 Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia) Suspended NCT00194636 Phase 4
7 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
8 Botox as a Treatment for Chronic Male Pelvic Pain Syndrome Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
9 Efficacy of Gralise® for Chronic Pelvic Pain Terminated NCT01678911 Phase 4 Gralise
10 Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli Terminated NCT02474706 Phase 4 Cefoxitin;imipenem
11 Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
12 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS) Completed NCT00919893 Phase 3 Cernilton;Placebo
13 Efficacy Study of Acupuncture to Relieve Symptoms of Chronic Prostatitis Completed NCT00260637 Phase 2, Phase 3
14 An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis Completed NCT00402688 Phase 3 levofloxacin;levofloxacin;levofloxacin
15 A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis Completed NCT00236808 Phase 3 levofloxacin
16 Levofloxacin, Chronic Bacterial Prostatitis Completed NCT00277511 Phase 3 Levofloxacin
17 Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00103402 Phase 3 Alfuzosin
18 Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA) Completed NCT00169585 Phase 3 Levofloxacin oral tablets
19 Complementary and Alternative Medicine for Urological Symptoms(CAMUS) Completed NCT00603304 Phase 3 Saw Palmetto - first 24 weeks;Placebo - first 24 weeks;Saw Palmetto - weeks 24 - 48;Placebo - weeks 24 - 48;Saw Palmetto - weeks 48 - 72;Placebo - weeks 48 - 72
20 "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk Completed NCT00056407 Phase 3 Dutasteride;Placebo
21 JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3 Jalyn;Placebo
22 Botulinum Toxin Type A for the Treatment of Male Chronic Pelvic Pain Syndrome Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
23 Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin Withdrawn NCT02975570 Phase 3 Delamanid;Linezolid;Levofloxacin;Pyrazinamide;WHO MDR-TB regimen
24 Laparoscopic Prostatectomy for Chronic Prostatitis Unknown status NCT00775515 Phase 2
25 Use of Silodosin to Treat Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Completed NCT00740779 Phase 2 Silodosin 8 mg;Placebo;Silodosin 4 mg
26 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00701311 Phase 2 CC-10004
27 Botox for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Completed NCT00529386 Phase 2 Botox;Lidocaine
28 An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis Completed NCT00826514 Phase 2 Tanezumab;Placebo
29 An Effectiveness and Safety Study of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Inflammation of the Prostate Gland Completed NCT00236990 Phase 2 pentosan polysulfate sodium
30 A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) Completed NCT01391338 Phase 2 ASP3652;Placebo
31 A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome Completed NCT00362752 Phase 2 Norfloxacin;Placebo
32 Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder Completed NCT00343356 Phase 2 Trement
33 Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Completed NCT00037141 Phase 1, Phase 2 dehydrated alcohol
34 Prulifloxacin in Chronic Bacterial Prostatitis (CBP) Recruiting NCT03201796 Phase 2 Prulifloxacin 600 mg;Levofloxacin 500mg
35 Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Recruiting NCT02961114 Phase 1, Phase 2
36 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
37 Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis Unknown status NCT00913315 tolterodine;tamsulosin;placebo
38 Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830
39 Non Interventional Study of Levofloxacin in Chronic Prostatitis Completed NCT02711943 Levofloxacin 500
40 Efficacy of Electromagnetic Stimulation Therapy for Chronic Prostatitis and Chronic Pelvic Pain Syndrome Completed NCT00922012
41 Chronic Pelvic Pain Study of Individuals With Diagnoses or Symptoms of Interstitial Cystitis and/ or Chronic Prostatitis Completed NCT01098279
42 Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT01843946
43 Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Completed NCT01826617
44 Role of Residual Urine and Asymptomatic Prostatitis in the Development of Urinary Tract Infections in Spinal Cord Injury Completed NCT01601041
45 Diagnostic Challenges in IC (and Male CPPS) Completed NCT00672087
46 2013 Annual National Digital Rectal Exam (DRE) Day Study Completed NCT01886547
47 Linkage Analysis in Interstitial Cystitis Completed NCT00675298
48 Observational Study of Control Participants for the MAPP Research Network Completed NCT01098292
49 Physical Therapy Trial for Pelvic Pain Completed NCT00434343
50 Sono-Electro-Magnetic Therapy for Refractory Chronic Pelvic Pain Syndrome Completed NCT00710073

Search NIH Clinical Center for Prostatitis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: prostatitis

Genetic Tests for Prostatitis

Anatomical Context for Prostatitis

MalaCards organs/tissues related to Prostatitis:

38
Prostate, Bone, Breast, Endothelial, Lymph Node, Testes, Lung

Publications for Prostatitis

Articles related to Prostatitis:

(show top 50) (show all 22115)
# Title Authors Year
1
Behaviour change techniques in physical activity interventions for men with prostate cancer: A systematic review. ( 29446325 )
2018
2
New prostate cancer grade grouping system predicts survival after radical prostatectomy. ( 29447924 )
2018
3
An integrative review exploring black men of African and Caribbean backgrounds, their fears of prostate cancer and their attitudes towards screening. ( 29444301 )
2018
4
Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography. ( 29430118 )
2018
5
Local recurrence on PET/CT with<sup>11</sup>C-choline following brachytherapy for prostate cancer: tracer uptake pattern. ( 29444756 )
2018
6
Procyanidin B2 3,3a8^-di-O-gallate induces oxidative stress-mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK. ( 28876465 )
2018
7
Anti-oxidants as chemopreventive agents in prostate cancer: A gap between preclinical and clinical studies. ( 29446748 )
2018
8
Cefoxitin-based antibiotic therapy for ESBL-producing Enterobacteriaceae prostatitis: a prospective pilot-study. ( 29378342 )
2018
9
Dioxin Exposure in the Manufacture of Pesticide Production as a Risk Factor for Death from Prostate Cancer: A Meta-analysis. ( 29445624 )
2018
10
Chronic reactive arthritis associated with prostatitis caused by<i>Neisseria meningitidis</i>. ( 29374652 )
2018
11
Letter to the Editor regarding the Article: "Anti-Inflammatory and Antimicrobial Effects of a Novel Herbal Formulation (WSY-1075) in a Chronic Bacterial Prostatitis Rat Model" by Park et al. World J Mens Health 2016;34(3):179-185. ( 29164832 )
2018
12
Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. ( 29105802 )
2018
13
Selective androgen receptor modulator S42 suppresses prostate cancer cell proliferation. ( 29444261 )
2018
14
Surgeon-Led Prostate Cancer Lymph Node Staging: Pathologic Outcomes Stratified by Robot-Assisted Dissection Templates and Patient Selection. ( 29446205 )
2018
15
Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. ( 29372565 )
2018
16
Lenalidomide decreased the PSA level for castration-resistant prostate cancer: a case report. ( 29445483 )
2018
17
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. ( 29448139 )
2018
18
Quantitative perineural invasion is a prognostic marker in prostate cancer. ( 29448999 )
2018
19
TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways. ( 29449534 )
2018
20
Long noncoding RNA PVT1 promotes EMT via mediating microRNA-186 targeting of Twist1 in prostate cancer. ( 29452232 )
2018
21
Coatomer subunit beta 2 (COPB2), identified by label-free quantitative proteomics, regulates cell proliferation and apoptosis in human prostate carcinoma cells. ( 29129687 )
2018
22
Retroperitoneal fibrosis associated with IgG4-related disease diagnosed by prostate biopsy developed with acute post-renal renal failure: A case report. ( 29034178 )
2018
23
Prospective comparative study of<sup>18</sup>F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer. ( 29447047 )
2018
24
Introducing a simple model system for binding studies of known and novel inhibitors of AMPK: a therapeutic target for prostate cancer. ( 29447108 )
2018
25
Volumetric-based image guidance is superior to marker-based alignments for stereotactic body radiotherapy of prostate cancer. ( 29450961 )
2018
26
Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma. ( 29445461 )
2018
27
Does a previous prostate biopsy-related acute bacterial prostatitis affect the results of radical prostatectomy? ( 29219284 )
2018
28
Severe prostate enlargement with severe lower urinary tract symptoms in poorly controlled acromegaly successfully treated with 5I+-reductase inhibitors: A 15-year longitudinal case report. ( 29405593 )
2018
29
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. ( 29335762 )
2018
30
Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer. ( 28422286 )
2018
31
Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth inA vitro and inA vivo. ( 29133261 )
2018
32
Prostate cancer-associated polyarteritis nodosa: improvement of clinical manifestations after prostatectomy. ( 29352851 )
2018
33
Do antibiotics decrease prostate-specific antigen levels and reduce the need for prostate biopsy in type IV prostatitis? A systematic literature review. ( 29173276 )
2018
34
The use of polysulfated polysaccharides heparin like compounds, glycosaminoglycans and Vitamin B17 as a possible treatment for prostate cancer. ( 29447928 )
2018
35
Association between male pattern baldness and prostate disease: A meta-analysis. ( 29054497 )
2018
36
Combined prostatic urethral lift and remodeling of the prostate and bladder neck: a modified transurethral approach in the treatment of symptomatic lower urinary tract obstruction. ( 29450732 )
2018
37
Differential research of inflammatory and related mediators in BPH, histological prostatitis and PCa. ( 29441606 )
2018
38
Role of MRI-targeted Biopsy in Detection of Prostate Cancer Harbouring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma. ( 29408568 )
2018
39
Prostate Artery Embolization for Complete Urinary Outflow Obstruction Due to Benign Prostatic Hypertrophy. ( 27853823 )
2017
40
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. ( 27546619 )
2017
41
ALDH1A3 correlates with luminal phenotype in prostate cancer. ( 28443495 )
2017
42
SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer. ( 27869166 )
2017
43
Primary bone lymphoma presenting as skeletal lesions in a patient recently treated for prostate cancer. ( 29164979 )
2017
44
Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. ( 28317149 )
2017
45
ALKBH7 Variant Related to Prostate Cancer Exhibits Altered Substrate Binding. ( 28231280 )
2017
46
Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer. ( 28910345 )
2017
47
Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization. ( 27321179 )
2017
48
MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer. ( 28241827 )
2017
49
A role of human beta defensin-1 in predicting prostatic adenocarcinoma in cases of false-negative biopsy. ( 28885732 )
2017
50
The Efflux Transporter ABCG2 Maintains Prostate Stem Cells. ( 27856956 )
2017

Variations for Prostatitis

Expression for Prostatitis

Search GEO for disease gene expression data for Prostatitis.

Pathways for Prostatitis

Pathways related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 CXCL8 IL10 IL1B IL6 TGFB1 TNF
2
Show member pathways
13.3 CXCL8 IL10 IL1B IL6 TGFB1 TNF
3
Show member pathways
13.24 CXCL8 IL10 IL1B IL6 TGFB1 TNF
4
Show member pathways
12.85 CXCL8 IL10 IL1B IL6 TGFB1 TNF
5 12.81 CXCL8 IL6 KLK3 NKX3-1 TGFB1
6
Show member pathways
12.65 IL1B IL6 TGFB1 TNF
7
Show member pathways
12.59 IL10 IL1B IL6 TGFB1 TNF
8
Show member pathways
12.55 IL10 IL1B IL6 TNF
9
Show member pathways
12.54 CXCL8 IL10 IL1B IL6 TGFB1 TNF
10
Show member pathways
12.53 CXCL8 IL6 TGFB1 TNF
11
Show member pathways
12.45 IL10 IL1B IL6 TGFB1 TNF
12
Show member pathways
12.32 CXCL8 IL1B IL6 TNF
13
Show member pathways
12.26 CXCL8 IL1B IL6 TNF
14
Show member pathways
12.25 IL10 IL1B TGFB1 TNF
15
Show member pathways
12.18 CXCL8 IL1B IL6 TNF
16
Show member pathways
12.17 CXCL8 IL10 IL1B IL6 TNF
17 12.16 IL10 IL1B IL6 TGFB1 TNF VDR
18 12.09 CXCL8 IL10 IL1B IL6 NKX3-1 TNF
19
Show member pathways
12.07 IL6 KLK3 TGFB1
20
Show member pathways
12.04 IL10 IL6 TGFB1
21 12.03 CXCL8 IL1B IL6 TGFB1 TNF
22 12.02 IL6 TGFB1 TNF
23 12 IL1B TGFB1 TNF
24 11.97 CXCL8 IL1B IL6 TGFB1
25 11.96 IL10 IL6 TNF
26
Show member pathways
11.94 IL10 IL1B IL6 TGFB1 TNF
27 11.92 IL1B IL6 TNF
28 11.9 CXCL8 IL1B IL6 TGFB1 TNF
29 11.87 IL1B IL6 TNF
30 11.86 CXCL8 IL1B TNF
31 11.85 CXCL8 IL1B IL6 TGFB1 TNF
32
Show member pathways
11.84 CXCL8 IL6 TGFB1
33
Show member pathways
11.83 IL1B IL6 TGFB1
34 11.8 CXCL8 IL1B IL6
35 11.79 CXCL8 IL10 IL1B IL6 TGFB1 TNF
36 11.77 IL10 IL1B TNF
37 11.76 CXCL8 IL10 IL1B IL6 TNF
38 11.74 IL10 IL6 TGFB1 TNF
39 11.72 IL10 IL1B IL6 TGFB1 TNF
40
Show member pathways
11.7 CXCL8 IL1B IL6 TNF
41 11.63 CXCL8 IL1B IL6 TNF
42 11.62 CXCL8 IL10 IL1B IL6 TGFB1 TNF
43 11.57 CXCL8 IL6 TGFB1
44 11.57 CXCL8 IL1B IL6 TGFB1 TNF
45 11.54 IL1B IL6 TNF VDR
46 11.53 IL1B TGFB1 TNF
47 11.53 IL1B KLK3 TNF
48 11.41 CXCL8 IL10 IL1B IL6 TNF
49
Show member pathways
11.39 IL10 TGFB1 TNF
50 11.39 IL10 IL1B IL6 TNF

GO Terms for Prostatitis

Cellular components related to Prostatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CXCL8 IL10 IL1B IL6 KLK3 MSMB
2 extracellular space GO:0005615 9.28 CXCL8 IL10 IL1B IL6 KLK3 MSMB

Biological processes related to Prostatitis according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.93 IL1B PROS1 TGFB1 TNF
2 positive regulation of transcription, DNA-templated GO:0045893 9.93 IL10 IL1B IL6 NKX3-1 TGFB1 TNF
3 positive regulation of protein phosphorylation GO:0001934 9.88 IL1B NKX3-1 TGFB1 TNF
4 regulation of receptor activity GO:0010469 9.88 CXCL8 IL10 IL1B IL6 TGFB1 TNF
5 response to organic substance GO:0010033 9.85 IL10 TGFB1 TNF
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 IL6 TGFB1 TNF
7 cellular response to organic cyclic compound GO:0071407 9.83 IL1B TGFB1 TNF
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 IL1B IL6 TGFB1 TNF
9 response to glucocorticoid GO:0051384 9.82 IL10 IL6 TNF
10 positive regulation of MAP kinase activity GO:0043406 9.81 PDE5A TGFB1 TNF
11 cellular response to lipopolysaccharide GO:0071222 9.8 CXCL8 IL10 IL6 TNF
12 inflammatory response GO:0006954 9.8 CXCL8 IL10 IL1B IL6 TGFB1 TNF
13 negative regulation of fat cell differentiation GO:0045599 9.78 IL6 TGFB1 TNF
14 positive regulation of interleukin-6 production GO:0032755 9.77 IL1B IL6 TNF
15 positive regulation of cell division GO:0051781 9.76 IL1B NKX3-1 TGFB1
16 positive regulation of DNA binding transcription factor activity GO:0051091 9.73 IL10 IL1B IL6 TNF
17 positive regulation of gene expression GO:0010628 9.73 IL1B IL6 NKX3-1 TGFB1 TNF VDR
18 negative regulation of T cell proliferation GO:0042130 9.71 IL10 PDE5A TGFB1
19 positive regulation of chemokine production GO:0032722 9.69 IL6 TNF
20 positive regulation of histone acetylation GO:0035066 9.69 IL1B TGFB1
21 embryonic digestive tract development GO:0048566 9.69 CXCL8 TNF
22 lipopolysaccharide-mediated signaling pathway GO:0031663 9.69 IL1B TGFB1 TNF
23 negative regulation of lipid catabolic process GO:0050995 9.68 IL1B TNF
24 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.68 IL1B TNF
25 negative regulation of growth of symbiont in host GO:0044130 9.68 IL10 TNF
26 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.68 IL1B TNF
27 response to molecule of bacterial origin GO:0002237 9.67 CXCL8 IL10
28 negative regulation of lipid storage GO:0010888 9.67 IL6 TNF
29 positive regulation of chemokine biosynthetic process GO:0045080 9.66 IL1B TNF
30 endothelial cell apoptotic process GO:0072577 9.65 IL10 TNF
31 regulation of establishment of endothelial barrier GO:1903140 9.65 IL1B TNF
32 negative regulation of cytokine secretion involved in immune response GO:0002740 9.63 IL10 TNF
33 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.62 NKX3-1 TNF
34 positive regulation of fever generation GO:0031622 9.61 IL1B TNF
35 sequestering of triglyceride GO:0030730 9.59 IL1B TNF
36 receptor biosynthetic process GO:0032800 9.57 IL10 TNF
37 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 IL1B TNF
38 positive regulation of mononuclear cell migration GO:0071677 9.55 TGFB1 TNF
39 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.54 IL10 IL1B TNF
40 protein kinase B signaling GO:0043491 9.46 IL1B NKX3-1 TGFB1 TNF
41 negative regulation of mitotic cell cycle GO:0045930 9.26 IL10 NKX3-1 TGFB1 TNF
42 negative regulation of cell proliferation GO:0008285 9.23 ADRA1A CXCL8 IL10 IL1B IL6 NKX3-1
43 immune response GO:0006955 10.02 CXCL8 IL10 IL1B IL6 TNF
44 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 IL10 IL1B IL6 NKX3-1 TGFB1 TNF

Molecular functions related to Prostatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.1 CXCL8 IL10 IL1B IL6 TGFB1 TNF

Sources for Prostatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....